Parkinson DiseasePhase 3ASPro-PDNCT05778617
Ambroxol to Slow Progression in Parkinson Disease
A Phase 3 study testing Ambroxol Hydrochloride (420mg) in people with Parkinson Disease, run by University College, London at 15 sites in United Kingdom.
Trial summary
This is a UK only clinical trial in patients with Parkinson's disease (PD) of a drug called ambroxol hydrochloride, which is an already licensed drug for the treatment of respiratory conditions (such as a common cold) in many European countries. Read more about this study
- Who is it for?
- Ages 35 to 75 years
- Conditions the study is for
- Parkinson Disease
- What is being tested?
- Ambroxol Hydrochloride (420mg)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 330 participants
- Where
- 15 sitesUnited Kingdom
- Study dates
- 25 Feb 2025to Sep 2029
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- A diagnosis of Parkinson's disease (in accordance with the MDS diagnostic criteria) within 7 years of the screening visit confirmed by year of diagnosis.
- Adults aged ≥ 35 and ≤ 75 years.
- Hoehn and Yahr stage between 1-2.5, inclusive (in ON stage) at screening visit.
- Known glucocerebrosidase gene (GBA1) status, positive or negative (status MUST be confirmed prior to screening).
- On stable dopaminergic treatment for at least 3 months before enrolment.
- Able and willing to provide informed consent prior to any study related assessments and/or procedures.
- Able and willing to attend trial visits and comply with all study procedures for the duration of the trial.
- Willing and able to self-administer oral ambroxol medication or placebo.
Who cannot join
- Participation in another interventional clinical trial of an Investigational Medicinal Product (IMP) and use of an Investigational Medicinal Product (IMP) within 90 days prior to the first dose of trial treatment.
- Use of an Investigational Medicinal Product (IMP) within 90 days prior to the first dose of trial treatment.
- Participation in another clinical trial of an Investigational New Drug being tested for PD disease modifying potential within 12 months prior to the first dose of trial treatment.
- Past surgical history of deep brain stimulation.
- Use of ambroxol in the past 12 months.
- Exposure to Exenatide within 12 months prior to the first dose in this current trial.
Show all 24Show fewer
- Concomitant medications that in the opinion of the Investigator would preclude participation in the study e.g., exenatide or other GLP1 agonist for diabetes.
- Confirmed dysphagia that would preclude self-administration of ambroxol.
- History of known sensitivity to the study medication, ambroxol or its excipients (lactose monohydrate, granulated microcrystalline cellulose, copovidone and magnesium stearate) in the opinion of the investigator that contraindicates their participation.
- History of known rare hereditary disorders of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
- Presence of the LRRK2 G2019S mutation (status to be confirmed prior to screening).
- History of drug abuse or alcoholism in the opinion of the Investigator that would preclude participation in the trial.
- Pregnant (or planned pregnancy during the trial) and/or breastfeeding.
- Women of childbearing potential (WOCBP) and male participants with a partner of childbearing potential not willing to use highly effective contraception or abstinence for the duration of the trial treatment and for 2 weeks following the last dose of the study drug.
- Any clinically significant or unstable medical or surgical condition that in the opinion of the Investigator may; put the participant at risk when participating in the study, influence the results of the study or affect the participants ability to take part in the study, as determined by medical history, physical examinations, electrocardiogram (ECG) or laboratory tests. Such conditions may include:
- Impaired renal function with creatinine clearance <50ml/min at screening visit.
- Moderate/Severe hepatic impairment.
- A major cardiovascular event (e.g., myocardial infarction, acute coronary syndrome, compensated congestive heart failure, pulmonary embolism, coronary revascularisation) that occurred within 6 months prior to the screening visit.
- Severe depression defined by a score >20 on the Beck Depression Inventory-II (BDI-II) at screening.
- Significant cognitive impairment defined by a score <20 on the Montreal Cognitive Assessment (MoCA) at screening.
- Use of trihexyphenidyl or benztropine within 30 days prior to the first dose of trial treatment.
- Only applicable for those patients consenting to the optional CSF sub-study: Evidence or history of hypersensitivity to lidocaine or its derivatives.
- Only applicable for those patients consenting to the optional CSF sub-study: current treatment with anti-coagulants (e.g., warfarin) that might preclude safe completion of the lumbar puncture in the opinion of the Investigator. Aspirin will be permitted.
- Only applicable for those patients consenting to the optional CSF sub-study: Significant known lower spinal malformations or other spinal abnormalities that would preclude a lumbar puncture.
Trial locations and contacts
15 sites in 1 country. Contact the study team or a site near you to ask about taking part.
15 sites in 1 country
United Kingdom15 sites, 15 recruiting
- Not yet recruiting
University Hospitals Birmingham
Birmingham
Ben Wright
Ben Wright, Dr
- Not yet recruiting
Southmead Hospital Bristol
Bristol
Alan Whone
Alan Whone, Dr
- Not yet recruiting
Addenbrookes NHS Trust
Cambridge
Caroline Williams-Gray
Caroline Williams-Gray, Dr
- Not yet recruiting
Western General Hospital
Edinburgh
David Breen
David Breen, Dr
- Not yet recruiting
Kings College London
London
Ray Chaudhuri
Ray Chaudhuri, Prof.
- Not yet recruiting
Royal London Hospital
London
Alastair Noyce
Alastair Noyce, Prof.
- Recruiting
University College London Hospital's
London
Marco Toffoli
Marco Toffoli, Dr
- Not yet recruiting
Newcastle
Newcastle
Nicola Pavese
Nicola Pavese, Prof.
- Not yet recruiting
Northumbria
Newcastle upon Tyne
James Fisher
James Fisher, Dr
- Not yet recruiting
The John Radcliffe Hospital
Oxford
Michele Hu
Michele Hu, Prof.
- Recruiting
Derriford Hospital
Plymouth
Stephen Mullin
Stephen Mullin, Dr
- Not yet recruiting
Fairfield General Hospital
Salford
Robert Irving
Robert Irving, Dr
- Recruiting
Salford Royal Hospital
Salford
Monty Silverdale
Monty Silverdale, Prof.
- Not yet recruiting
Southampton General Hospital
Southampton
Boyd Ghosh
Boyd Ghosh, Dr
- Not yet recruiting
Prince Philip Hospital
Wales
Mark Sheehan
Mark Sheehan, Dr
About this study
Official title: Ambroxol to Slow Progression in Parkinson Disease: A Phase IIIa Multi-centre Randomised Placebo-controlled Trial
This is a UK only clinical trial in patients with Parkinson's disease (PD) of a drug called ambroxol hydrochloride, which is an already licensed drug for the treatment of respiratory conditions (such as a common cold) in many European countries. The aim of this trial is to find out whether ambroxol hydrochloride can slow down the progression of Parkinson's disease and to evaluate it's safety and tolerability.
Read the detailed description
This is a 104-week, randomized, double-blind, multi-centre, parallel group, placebo-controlled clinical trial of ambroxol hydrochloride in patients with PD, with a 26-week open-label extension phase. Participants will undergo screening to evaluate their eligibility to participate in the trial. All eligible participants will be randomised to receive either ambroxol hydrochloride (420mg) or it's matching placebo in a 1:1 ratio three times a day for 104 weeks, including a 2-week dose escalation period. Once the end of the blinded treatment has been reached, all participants will enter the open-label extension phase and will receive ambroxol hydrochloride (420mg) three times a day for 26 weeks, including a 2-week dose escalation period. All clinical staff, study investigators, and participants will be blinded to study assignments throughout the entirety of the trial.
There will be an optional sub-study including 106 participants in which a cerebrospinal fluid (CSF) sample will be taken on two occasions via a Lumbar Puncture procedure to measure ambroxol drug levels, assess whether the glucocerebrosidase enzyme has been stimulated and the levels of other substances thought to be associated with the development of PD and confirm whether the study drug has penetrated the cerebrospinal fluid and Central Nervous System.
- Conditions
- Parkinson Disease
- Being tested
- Ambroxol Hydrochloride (420mg), Placebo
- Keywords
- Parkinsonian Disorders, Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Movement Disorders, Neurodegenerative Diseases, Ambroxol, Synucleinopathies
- Medical subject headings
- Parkinson Disease, Parkinsonian Disorders, Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Movement Disorders, Neurodegenerative Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ambroxol Hydrochloride (420mg)Drug
Also called Ambroxol
Oral tablet
PlaceboDrug
Oral tablet
| Study group | Role | What they receive |
|---|---|---|
| Ambroxol hydrochloride | Active comparator | Participants will receive ambroxol hydrochloride (tablets) for 104 weeks (blinded treatment period). Participants will receive ambroxol hydrochloride 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the blinded treatment period. Participants will then enter the open-label extension and will receive ambroxol hydrochloride 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the open-label extension phase.
n=165 Receives: Drug: Ambroxol Hydrochloride (420mg) |
| Placebo | Placebo comparator | Participants will receive ambroxol hydrochloride matching placebo (tablets) for 104 weeks (blinded treatment period). Participants will receive ambroxol hydrochloride matching placebo 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the blinded treatment period. Participants will then enter the open-label extension and will receive ambroxol hydrochloride 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the open-label extension phase.
n=165 Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I- III score from baseline to Week 104.
The MDS-UPDRS is a comprehensive 50 question assessment of both motor and non-motor symptoms associated with Parkinson's. Comparison of MDS-UPDRS Parts I-III total score at 104 weeks between participants according to treatment allocation will be made. Parts I and II are measured in the practically defined ON medication state and Part III is measured in the practically defined OFF medication state. Parts I and II are historical data assessed by an examiner and are designed to rate mentation, behaviour and mood; Part III is done as a motor examination at the time of a visit. Participants will undergo MDS-UPDRS assessment at baseline, week 20, week 40, week 60, week 80, week 104. The MDS-UPDRS measures patient status on a scale 0, which is normal or none, to 4, which is severe or the worst scenario. MDS-UPDRS score = sum of Parts I, II and III (Range: 0 to 236). Higher score indicative of worse outcome.
Measured: Baseline; Week 104
Secondary outcomes (43)
Motor signs of PD using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III score in the OFF medication state from baseline to Week 104.
This component of the MDS-UPDRS scale (Section III) assesses the motor signs of PD and will involve a motor examination at the time of a visit. The score ranges from 0 to 132. Higher score is indicative of worse outcome.
Measured: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.
Motor complications of PD using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part IV score in the ON medication state from baseline to Week 104.
This component of the MDS-UPDRS scale (Section IV) assesses two motor complications, dyskinesias and motor fluctuations using historical and objective information. The score ranges from 0 to 24. Higher score indicative of worse outcome.
Measured: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.
The non-motor impact of PD on patients using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part I score in the ON medication state baseline to Week 104.
This component of the MDS-UPDRS scale (Section I) assesses the non-motor impact of Parkinson's disease (PD) on patients' experiences of daily living. The score ranges from 0 to 24. Higher score indicative of worse outcome.
Measured: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.
The motor aspect impact of PD of patients experiences on daily living using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part II score in the ON medication state from baseline to Week 104.
This component of the MDS-UPDRS scale (Section II) assesses the motor aspect impact of Parkinson's disease (PD) on patients' experiences of daily living. The score ranges from 0 to 52. Higher score indicative of worse outcome.
Measured: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.
The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) tremor score from baseline to Week 104.
The tremor components of the MDS-UPDRS scale
Measured: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.
The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) non-tremor score from baseline to Week 104.
The non-tremor components of the MDS-UPDRS scale
Measured: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.
Cognitive impairment using the Montreal Cognitive Assessment from baseline to Week 104.
A 30 question test which assesses mild cognitive impairment by checking participant orientation, short-term memory, executive function, language, abstraction, naming of animals, attention and a clock drawing test. Maximum score= 30. Lower scores indicative of worse outcome.
Measured: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Patient reported measure of health status and quality of life using the Parkinson's disease 39 item Quality of Life questionnaire from baseline to Week 104.
A questionnaire which assesses how often people affected by Parkinson's experience difficulties across 8 dimensions of daily living. The 39 item questionnaire offers a patient reported measure of health status and quality of life and is the most frequently used disease-specific health status measure. Maximum score = 156. Higher score= worse outcome.
Measured: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Symptom improvement from baseline to Week 104 using the Patient Global Impression of Change from baseline to Week 104.
A 1 item questionnaire which asks a participant to report their own impression of change in their clinical status. Maximum score = 7. Higher score= worse outcome.
Measured: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Quality-of-Life outcome differences between the two treatment groups from baseline to Week 104, as measured by the descriptive system for health-related quality of life, EQ-5D-5L.
The EQ-5D-5L is a participant self-reported questionnaire which evaluates the generic quality of life at the time of completion. It comprises of one question for each of the five dimensions ;no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate their health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. An Visual Analogue Scale is also used and is a scale measured from 0 -100 scale where patients are asked to indicate their overall health on the day of questionnaire completion. Maximum score = 100. Lower score = worse outcome.
Measured: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Non-motor symptoms of PD from baseline to Week 104 , as measured by the Non-Motor Symptoms Scale.
The Non-Motor Symptoms Scale (NMSS) is a 30-item rater-based scale to assess a wide range of non-motor symptoms in patients with Parkinson's disease (PD). The NMSS measures the severity and frequency of non-motor symptoms across nine dimensions. Maximum score = 360. Higher score = worse outcome.
Measured: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
PD progression measured using Parkinson's Disease Comprehensive Response from baseline to Week 104
A composite approach integrating three standard outcome measures PDCORE = (1 × change in OFF state motor score) + (2 × change in OFF state ADL score) - (10 × change in total good-quality ON time per day). Higher score = worse outcome.
Measured: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Assessment of postural instability and falls from baseline to Week 104 using the Dresden Falls Questionnaire.
A self-reported assessment of falls, near falls, fear of falling, fall-related injuries, and causes of falls for patients with Parkinson's disease. Maximum score = 12. Higher score = worse outcome.
Measured: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Symptom severity, treatment response and the efficacy of treatment from baseline to Week 104 using the Clinical Global Impression of symptom severity and improvement scales.
Research team assessment. The CGI has two components-the CGI-Severity, which rates illness severity, and the CGI-Improvement, which rates change from the initiation (baseline) of treatment. Maximum score = 14. Higher score = worse outcome.
Measured: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in pulse (bpm) from baseline to Week 104
Vital signs
Measured: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in blood pressure (mmHg) from baseline to Week 104
Vital signs
Measured: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in temperature (°) from baseline to Week 104
Vital signs
Measured: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in respiratory rate (breaths per minute)from baseline to Week 104
Vital signs
Measured: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Body Mass Index (weight and height will be combined to report BMI in kg/m^2) from baseline to Week 104
Vital signs
Measured: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Red Blood Cell Count (10^12/L) from baseline to Week 104
Standard diagnostic laboratory test (Full Blood Count)
Measured: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Haemoglobin (g/dL) from baseline to Week 104
Standard diagnostic laboratory test (Full Blood Count)
Measured: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Haematocrit (%) from baseline to Week 104
Standard diagnostic laboratory test (Full Blood Count)
Measured: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Platelets (10^9/L) from baseline to Week 104
Standard diagnostic laboratory test (Full Blood Count)
Measured: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in White Blood Cell Count (10^9/L) from baseline to Week 104
Standard diagnostic laboratory test (Full Blood Count)
Measured: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Neutrophils (10^9/L) from baseline to Week 104
Standard diagnostic laboratory test (Full Blood Count)
Measured: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Eosinophils (10^9/L) from baseline to Week 104
Standard diagnostic laboratory test (Full Blood Count)
Measured: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Basophils (10^9/L) from baseline to Week 104
Standard diagnostic laboratory test (Full Blood Count)
Measured: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Lymphocytes (10^9/L) from baseline to Week 104
Standard diagnostic laboratory test (Full Blood Count)
Measured: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Monocytes (10^9/L) from baseline to Week 104
Standard diagnostic laboratory test (Full Blood Count)
Measured: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Urea (mmol/L) from baseline to Week 104
Standard diagnostic laboratory test (Biochemistry)
Measured: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Sodium (mmol/L) from baseline to Week 104
Standard diagnostic laboratory test (Biochemistry)
Measured: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Potassium (mmol/L) from baseline to Week 104
Standard diagnostic laboratory test (Biochemistry)
Measured: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Creatinine (µmol/L) from baseline to Week 104
Standard diagnostic laboratory test (Biochemistry)
Measured: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Total Bilirubin (µmol/L)from baseline to Week 104
Standard diagnostic laboratory test (Biochemistry)
Measured: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Alkaline phosphatase (IU/L) from baseline to Week 104
Standard diagnostic laboratory test (Biochemistry)
Measured: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Alanine transaminase (IU/L) from baseline to Week 104
Standard diagnostic laboratory test (Biochemistry)
Measured: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Aspartate Aminotransferase (IU/L) from baseline to Week 104
Standard diagnostic laboratory test (Biochemistry)
Measured: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Uric Acid (mg/dL) from baseline to Week 104
Standard diagnostic laboratory test (Biochemistry)
Measured: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Bicarbonate (mmol/L) from baseline to Week 104
Standard diagnostic laboratory test (Biochemistry)
Measured: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Chloride (mmol/L) from baseline to Week 104
Standard diagnostic laboratory test (Biochemistry)
Measured: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by the occurrence / severity of treatment related Adverse Events assessed by CTCAE v5.0 from baseline to Week 104
Number of participants with treatment related adverse events assessed by CTCAE v5.0 from baseline to Week 104.
Measured: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Time to initiation of rescue medication
Length of time until initiation of rescue medication from baseline to Week 104.
Measured: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Change in levodopa equivalent dose at 104 weeks
Calculated levodopa equivalent dose from baseline to Week 104.
Measured: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Mar 2023
- Study start25 Feb 2025
- Primary completionFeb 2029 (estimated)
- Study completionSep 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- More trials run by University College, LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- A randomised, double blind, parallel group, placebo controlled, Phase 3a trial of daily ambroxol hydrochloride (420mg) as a potential disease modifying treatment for Parkinson's disease.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 330 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University College, London
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Anthony Schapira, Principal investigator, University College, London
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05778617
- Sponsor's protocol ID
- CCTU/2020/365
- Acronym
- ASPro-PD
- Status last verified
- Apr 2025
- First submitted
- 16 Feb 2023
- Last updated
- 1 May 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 1 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ambroxol to Slow Progression in Parkinson Disease: A Phase IIIa Multi-centre Randomised Placebo-controlled Trial
- ClinicalTrials.gov ID
- NCT05778617
- Acronym / sponsor ID
- ASPro-PD / CCTU/2020/365
- Conditions
- Parkinson Disease
- Keywords
- Parkinsonian Disorders, Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Movement Disorders, Neurodegenerative Diseases, Ambroxol
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 330 participants (estimated)
- Lead sponsor
- University College, LondonUniversity, hospital or other
- Study start
- 25 Feb 2025 (actual)
- Primary completion
- Feb 2029 (estimated)
- Study completion
- Sep 2029 (estimated)
- First posted
- 21 Mar 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a UK only clinical trial in patients with Parkinson's disease (PD) of a drug called ambroxol hydrochloride, which is an already licensed drug for the treatment of respiratory conditions (such as a common cold) in many European countries. The aim of this trial is to find out whether ambroxol hydrochloride can slow down the progression of Parkinson's disease and to evaluate it's safety and tolerability.
Detailed description
This is a 104-week, randomized, double-blind, multi-centre, parallel group, placebo-controlled clinical trial of ambroxol hydrochloride in patients with PD, with a 26-week open-label extension phase. Participants will undergo screening to evaluate their eligibility to participate in the trial. All eligible participants will be randomised to receive either ambroxol hydrochloride (420mg) or it's matching placebo in a 1:1 ratio three times a day for 104 weeks, including a 2-week dose escalation period. Once the end of the blinded treatment has been reached, all participants will enter the open-label extension phase and will receive ambroxol hydrochloride (420mg) three times a day for 26 weeks, including a 2-week dose escalation period. All clinical staff, study investigators, and participants will be blinded to study assignments throughout the entirety of the trial.
There will be an optional sub-study including 106 participants in which a cerebrospinal fluid (CSF) sample will be taken on two occasions via a Lumbar Puncture procedure to measure ambroxol drug levels, assess whether the glucocerebrosidase enzyme has been stimulated and the levels of other substances thought to be associated with the development of PD and confirm whether the study drug has penetrated the cerebrospinal fluid and Central Nervous System.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- A randomised, double blind, parallel group, placebo controlled, Phase 3a trial of daily ambroxol hydrochloride (420mg) as a potential disease modifying treatment for Parkinson's disease.
| Arm | Type | Receives |
|---|---|---|
| Ambroxol hydrochloride | Active comparator | Drug: Ambroxol Hydrochloride (420mg)Participants will receive ambroxol hydrochloride (tablets) for 104 weeks (blinded treatment period). Participants will receive ambroxol hydrochloride 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the blinded treatment period. Participants will then enter the open-label extension and will receive ambroxol hydrochloride 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the open-label extension phase. n=165 |
| Placebo | Placebo comparator | Drug: PlaceboParticipants will receive ambroxol hydrochloride matching placebo (tablets) for 104 weeks (blinded treatment period). Participants will receive ambroxol hydrochloride matching placebo 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the blinded treatment period. Participants will then enter the open-label extension and will receive ambroxol hydrochloride 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the open-label extension phase. n=165 |
Who may qualify
- Ages
- 35 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- A diagnosis of Parkinson's disease (in accordance with the MDS diagnostic criteria) within 7 years of the screening visit confirmed by year of diagnosis.
- Adults aged ≥ 35 and ≤ 75 years.
- Hoehn and Yahr stage between 1-2.5, inclusive (in ON stage) at screening visit.
- Known glucocerebrosidase gene (GBA1) status, positive or negative (status MUST be confirmed prior to screening).
- On stable dopaminergic treatment for at least 3 months before enrolment.
Key exclusion criteria (24 listed)
- Participation in another interventional clinical trial of an Investigational Medicinal Product (IMP) and use of an Investigational Medicinal Product (IMP) within 90 days prior to the first dose of trial treatment.
- Use of an Investigational Medicinal Product (IMP) within 90 days prior to the first dose of trial treatment.
- Participation in another clinical trial of an Investigational New Drug being tested for PD disease modifying potential within 12 months prior to the first dose of trial treatment.
- Past surgical history of deep brain stimulation.
- Use of ambroxol in the past 12 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ambroxol Hydrochloride (420mg)Also: AmbroxolOral tablet | Drug | Ambroxol hydrochloride |
| PlaceboOral tablet | Drug | Placebo |
Primary outcome
Change in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I- III score from baseline to Week 104.
Time frame: Baseline; Week 104
The MDS-UPDRS is a comprehensive 50 question assessment of both motor and non-motor symptoms associated with Parkinson's. Comparison of MDS-UPDRS Parts I-III total score at 104 weeks between participants according to treatment allocation will be made. Parts I and II are measured in the practically defined ON medication state and Part III is measured in the practically defined OFF medication state. Parts I and II are historical data assessed by an examiner and are designed to rate mentation, behaviour and mood; Part III is done as a motor examination at the time of a visit. Participants will undergo MDS-UPDRS assessment at baseline, week 20, week 40, week 60, week 80, week 104. The MDS-UPDRS measures patient status on a scale 0, which is normal or none, to 4, which is severe or the worst scenario. MDS-UPDRS score = sum of Parts I, II and III (Range: 0 to 236). Higher score indicative of worse outcome.
43 secondary outcomes
Motor signs of PD using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III score in the OFF medication state from baseline to Week 104.
Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.
Motor complications of PD using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part IV score in the ON medication state from baseline to Week 104.
Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.
The non-motor impact of PD on patients using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part I score in the ON medication state baseline to Week 104.
Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.
The motor aspect impact of PD of patients experiences on daily living using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part II score in the ON medication state from baseline to Week 104.
Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.
The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) tremor score from baseline to Week 104.
Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.
The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) non-tremor score from baseline to Week 104.
Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.
Cognitive impairment using the Montreal Cognitive Assessment from baseline to Week 104.
Time frame: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Patient reported measure of health status and quality of life using the Parkinson's disease 39 item Quality of Life questionnaire from baseline to Week 104.
Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Symptom improvement from baseline to Week 104 using the Patient Global Impression of Change from baseline to Week 104.
Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Quality-of-Life outcome differences between the two treatment groups from baseline to Week 104, as measured by the descriptive system for health-related quality of life, EQ-5D-5L.
Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Non-motor symptoms of PD from baseline to Week 104 , as measured by the Non-Motor Symptoms Scale.
Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
PD progression measured using Parkinson's Disease Comprehensive Response from baseline to Week 104
Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Assessment of postural instability and falls from baseline to Week 104 using the Dresden Falls Questionnaire.
Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Symptom severity, treatment response and the efficacy of treatment from baseline to Week 104 using the Clinical Global Impression of symptom severity and improvement scales.
Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in pulse (bpm) from baseline to Week 104
Time frame: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in blood pressure (mmHg) from baseline to Week 104
Time frame: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in temperature (°) from baseline to Week 104
Time frame: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in respiratory rate (breaths per minute)from baseline to Week 104
Time frame: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Body Mass Index (weight and height will be combined to report BMI in kg/m^2) from baseline to Week 104
Time frame: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Red Blood Cell Count (10^12/L) from baseline to Week 104
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Haemoglobin (g/dL) from baseline to Week 104
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Haematocrit (%) from baseline to Week 104
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Platelets (10^9/L) from baseline to Week 104
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in White Blood Cell Count (10^9/L) from baseline to Week 104
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Neutrophils (10^9/L) from baseline to Week 104
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Eosinophils (10^9/L) from baseline to Week 104
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Basophils (10^9/L) from baseline to Week 104
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Lymphocytes (10^9/L) from baseline to Week 104
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Monocytes (10^9/L) from baseline to Week 104
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Urea (mmol/L) from baseline to Week 104
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Sodium (mmol/L) from baseline to Week 104
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Potassium (mmol/L) from baseline to Week 104
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Creatinine (µmol/L) from baseline to Week 104
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Total Bilirubin (µmol/L)from baseline to Week 104
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Alkaline phosphatase (IU/L) from baseline to Week 104
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Alanine transaminase (IU/L) from baseline to Week 104
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Aspartate Aminotransferase (IU/L) from baseline to Week 104
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Uric Acid (mg/dL) from baseline to Week 104
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Bicarbonate (mmol/L) from baseline to Week 104
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Chloride (mmol/L) from baseline to Week 104
Time frame: At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 May 2025.
- ASPro-PD Trial WebsiteLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided
Related trials for Parkinson Disease
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Anthony Schapira principal investigator
University College, London
15 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Ambroxol Hydrochloride (420mg) in people with Parkinson Disease, run by University College, London at 15 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 1 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 15 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact ASPro-PD Trial Team (02031084908, cctu.aspro-pd@ucl.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I- III score from baseline to Week 104. (time frame: Baseline; Week 104). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2025.